Discontinuation report TEVA-IRBESARTAN HCTZ
Report ID | 231577 |
Drug Identification Number | 02330520 |
Brand name | TEVA-IRBESARTAN HCTZ |
Common or Proper name | IRBESARTAN HCTZ |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | IRBESARTAN HYDROCHLOROTHIAZIDE |
Strength(s) | 300MG 12.5MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 100 |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for discontinuation | Business reasons |
Anticipated discontinuation date | 2024-06-28 |
Actual discontinuation date | 2024-06-28 |
Remaining supply date | 2024-06-28 |
Discontinuation status | Discontinued |
Discontinuation decision reversal | No |
Information on remaining supply | |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v3 | 2024-06-29 | English | Compare |
v2 | 2024-06-28 | French | Compare |
v1 | 2024-06-28 | English | Compare |
Showing 1 to 3 of 3